Reabilitação termo-higrométrica de edifícios de estabelecimentos de ensino construídos entre a década de 60 e 90

Em consequência da elevada permanência das pessoas em espaços interiores de edifícios, surge actualmente uma maior preocupação com o conforto térmico e qualidade do ar no seu interior. Apesar da grande evolução tecnológica dos sistemas de conservação de energia térmica e controle da qualidade do ar interior (QAI) na construção, os edifícios existentes acabam por não acompanhar essa evolução, apresentando um comportamento térmico e higrométrico que por vezes podem comprometer quer o conforto, quer a saúde e actividades dos seus utilizadores. Nos estabelecimentos de ensino, o comportamento termo-higrométrico assume um papel importante face à permanência diária de um grande número de crianças e jovens no seu interior. Com este estudo pretende-se caracterizar a qualidade do ambiente no interior de oito escolas, através de uma análise aos principais parâmetros de natureza higrotérmica de oito salas de aulas, tais como: a temperatura (ambiente e superficial), a humidade relativa (do ambiente e da superfície da envolvente exterior opaca), bem como o nível de escoamento do ar interior. Neste trabalho são apresentados os resultados das medições efectuadas em oito salas de aula que permitiram a comparação de características termo-higrométricas entre as respectivas escolas. É ainda apresentada a estimativa do nível de conforto térmico face às condições ambientais registadas, bem como a análise do risco de ocorrência de condensações interiores.

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Recueil de poésies, par « HENRY BAULDE » (fol. 30, 32, 35, 36, 37, 39, 40, 43, 44, 46, 47, 56, 59, 60, 61, 65, 68, 69, 70, 73, 74), « ALAIN CHARRETIER » (fol. 15), « JEHAN DAUTON » (fol. 9), « JEHAN MAROT » (fol. 29, 30), « JEHAN MOLINET » (fol. 77, 85, 90, 93, 94, 95) et « JEHAN ROBERTET » (fol. 1, 75).

Commençant par : « Estant couché soubz ung myrthe plaisant, Et maintz chasteaulx en Espaigne faisant... » et finissant par : « Sans parage ou riens n'est nect, Moulu d'un groz Moulinet. Fin de la complaincte de Grece, composée par le dict Molinet » .

Resolución N° 90 del 18 de mayo de 2010 ¿Seria violatoría la reunión por derecho propio aun en contra de la voluntad de los administradores o socios?

Servicios registrales

The War, 8 March 1814 (vol. 2, no. 38, whole no. 90) - Newspaper

Volumes of interest were published between 1812 and 1815 with articles about the War of 1812.

HG 238.80-238.90 Thin Section

Dark brown sediment with clasts ranging from small to medium in size and sub-angular to angular. Contains lineations and grain stacking throughout the sample. Rotation and comet structures can also be seen. Rotation structures can be seen around mainly the sub-angular clasts. Patches of clay can also be seen throughout the sample.

DE #6 260.90-261.0

Coarse grained sediment with clasts ranging from small to medium in size. Clast shape range from sub-angular to sub-rounded. Lineations are present throughout the sample. Edge-to-edge grain crushing, grain stacking, and comet structures can also be seen. Some grains are crushed into one another. Areas of finer sediment can also be seen.

HG 367.80-367.90

Dark grey sediment with clasts that range from small to medium. The clasts are mainly sub-rounded. Lineations are abundant with minor amounts of rotation structures and comet structures. Grain crushing can also be seen throughout the sample.

HG 493.80-493.90

Coarse brown sediment, with clasts ranging from small to large in size. Clast shape ranges from sub-angular to rounded. Lineations and grain crushing are common throughout the sample. It also contains comet structures and a few rotation structures. Many of the larger clasts are also fractured.

HG 28.75-28.90

This sample contains clasts that range from small to large. A few fractured grains can be seen. The grain shape ranges from angular to rounded. Rotation structures can be seen throughout the sample along with some edge-to-edge grain crushing.